Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively
Follow your physician's dosage instructions precisely
No Hidden Fees - Pricing starts at $250 regardless of dosage, and you won't deal with memberships or insurance requirements
Circulation 144 , 506508 (2021)
Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis
Yes, creatine can generally be used alongside tirzepatide, but the decision requires individualized clinical assessment